In the assessment of 12-month price targets, analysts unveil insights for Sangamo Therapeutics, presenting an average target ...

Sangamo (SGMO) delivered earnings and revenue surprises of -22.22% and 52.51%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

SANGAMO THERAPEUTICS ($SGMO) posted quarterly earnings results on Monday, March 17th. The company reported earnings of -$0.11 per share, missing estimates of -$0.09 ...

Sangamo Therapeutics Inc. SGMO) on Monday reported a loss of $23.4 million in its fourth quarter.

The company said, “2025 operating expenses on a non-GAAP basis are expected to be roughly in line with 2024, reflecting our intention to ...

This shortfall highlights the company’s ongoing revenue challenges. Following the earnings release, Sangamo’s stock saw a minor decline of 0.12% in aftermarket trading, closing at $0.98.

Shares of clinical-stage biotech firm Sangamo Therapeutics Inc. fell nearly 3% in Monday's after-hours trading following ...

Today, several major companies are expected to report earnings: CBAK Energy Technology (CBAT), Sangamo Biosciences (SGMO), ...

This shortfall highlights the company’s ongoing revenue challenges. Following the earnings release, Sangamo’s stock saw a minor decline of 0.12% in aftermarket trading, closing at $0.98. With a beta ...

RICHMOND, Calif. (AP) — RICHMOND, Calif. (AP) — Sangamo Therapeutics Inc. (SGMO) on Monday reported a loss of $23.4 million in its fourth quarter. On a per-share basis, the Richmond ...

SANGAMO THERAPEUTICS ($SGMO) is expected to release its quarterly earnings data on Monday, March 17th after market close, per Finnhub. Analysts are expecting revenue ...